Plain-English translation of NCT05930665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing cadonilimab, a new immunotherapy drug, combined with bevacizumab (an anti-cancer medication) and two chemotherapy drugs (pemetrexed and carboplatin) for people with pleural mesothelioma—a serious cancer of the lung lining that cannot be treated with surgery. Cadonilimab works by helping your immune system recognize and fight cancer cells. The study aims to see if this four-drug combination is effective and safe as a first-line treatment.
Pleural mesothelioma is a hard-to-treat cancer, and people who cannot have surgery need better treatment options. This medication is designed to boost the immune system's ability to fight cancer while potentially having fewer side effects than similar treatments already available.
You would receive the four-drug combination through infusions and pills over 4 to 6 treatment cycles (typically given every 3 weeks). After the initial cycles, you would continue with maintenance treatment using two of the medications. You would have regular clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study will involve roughly 38 participants and is currently recruiting.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China